Gb Sciences INC

GB Sciences has entered an exclusive licensing agreement with EndoPure Life Sciences for its cannabinoid-based Parkinson's treatment, securing a 5% royalty on gross sales and funding for first-in-human clinical trials in South America.

GB Sciences appoints Dr. Andrea Small-Howard as CEO, CFO, and Chairman of the Board following the passing of former CEO John Poss.

GB Sciences has signed a non-binding letter of intent with EndoPure Life Sciences to license its intellectual property for pharmaceutical product development and marketing in South America.

GB Sciences reported its first revenue from a new licensing agreement in Q3 2025, alongside reduced operating losses, but continues to face substantial doubt about its ability to continue as a going concern due to significant accumulated deficit and liquidity challenges.

GB Sciences reports its second quarter results for fiscal year 2025, highlighting ongoing drug development efforts and expansion of its intellectual property portfolio.

GB Sciences reports a net loss for the quarter ended June 30, 2024, while continuing to advance its drug development programs and intellectual property portfolio.

GB Sciences, a biopharmaceutical company, released its third quarter 2024 results, showcasing advancements in its drug development programs and intellectual property portfolio, while also noting ongoing financial challenges.

GB Sciences' annual 10-K filing highlights positive preclinical results across multiple therapeutic programs and a significant increase in their patent portfolio.